• citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:33
  • full-text downloads in 30 days:0


article: 3 from 5  
Back back to result list
2017, vol. 74, iss. 11, pp. 1084-1088
Bisphosphonate related osteonecrosis of the maxilla: A case report
aUniversity of Novi Sad, Faculty of Medicine, Department of Dentistry and Maxillofacial and Oral Surgery + University of Novi Sad, Faculty of Medicine
bMilitary Medical Academy, Clinic of Maxillofacial Surgery, Belgrade + University of Kragujevac, Faculty of Medical Sciences
Keywords: bisphosphonate-associated osteonecrosis of the jaws; diagnosis; drug therapy; oral surgical procedures; treatment outcome
Introduction. Bisphosphonates are a group of medications which have an important role in the treatment of some bone diseases. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of intravenous bisphosphonate therapy. The mechanism of action by which they may cause osteonecrosis is questionable. BRONJ is defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS) and classified into four stages (0-3). Treatment of BRONJ depends on the stage of disease and includes conservative treatment (stage 0 and 1) and surgical treatment (surgical debridement in stage 2 and sequestrectomy in stage 3). Case report. We presented a patient who had breast cancer, with stage 3 of bisphosphonate-related osteonecrosis of the upper jaw after zoledronic acid therapy for diffuse metastasis of the vertebrae. Before the treatment with zoledronic acid the patient was treated by a dentist. The osteonecrosis of the upper jaw started a year and a half after the start of zoledronic acid therapy and after tooth 24 extraction. She was treated by an oral surgeon at the beginning according to the protocol of AAOMS. The patient was sent to a maxillofacial surgeon due to the disease progression, and after computed tomography (CT) examination resection of the upper jaw was done. Conclusion. BRONJ is a condition with the specific clinical presentation, and it can be very serious for the patient, therefore it is necessary to emphasize the importance of screening. The doctors in different specialties (oncologist, dentist, oral surgeon and maxillofacial surgeon) must cooperate and control the patients under treatment with bisphosphonates before the therapy starts, as well as during and after it, in order to prevent, recognize on time and treat properly this complication.
Agrillo, A., Filiaci, F., Ramieri, V., Riccardi, E., Quarato, D., Rinna, C., i dr. (2012) Bisphosphonate-related osteonecrosis of the jaw(BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci, 16(12): 1741−7
Bagan, J., Scully, C., Sabater, V., Jimenez, Y. (2009) Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncology, 45(7): 551-554
Brandi, M. (2009) Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. Therapeutics and Clinical Risk Management, str. 217
Bucur, A. (2011) A Case Series of Osteoporosis Patients Affected by Bisphosphonate-Related Osteonecrosis of the Jaws. Acta Endocrinologica (Bucharest), 7(4): 483-490
Carlson, E.R., Basile, J.D. (2009) The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery, 67(5): 85-95
Filleul, O., Crompot, E., Saussez, S. (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. Journal of Cancer Research and Clinical Oncology, 136(8): 1117-1124
Loncarevic, S., Brajkovic, D., Vukomanovic-Djurdjevic, B., Kanjevac, T., Vasovic, M. (2015) Bilateral numb chin syndrome as a symptom of breast cancer metastasis in the mandible: A case report and discussion on the usefulness of cone-beam computed tomography to assess bone involvement in oral cancer. Oral Radiology, 1-7
Marx, R.E. (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg, 61(9): 1115-7
Mücke, T., Haarmann, S., Wolff, K., Hölzle, F. (2009) Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. Journal of Cranio-Maxillofacial Surgery, 37(5): 291-297
Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., Janecek, E., Domecq, C., Greenblatt, D.J. (1981) A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30(2): 239-245
Pautke, C., Otto, S., Reu, S., Kolk, A., Ehrenfeld, M., Stürzenbaum, S., Wolff, K. (2011) Bisphosphonate related osteonecrosis of the jaw - Manifestation in a microvascular iliac bone flap. Oral Oncology, 47(5): 425-429
Reid, I.R., Cornish, J. (2011) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews Rheumatology
Ruggiero, S.L., Dodson, T.B., Assael, L.A., Landesberg, R., Marx, R.E., Mehrotra, B. (2009) American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update. Journal of Oral and Maxillofacial Surgery, 67(5): 2-12
Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J., Engroff, S.L. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery, 62(5): 527-534
Tardast, A., Sjöman, R., Løes, S., Abtahi, J. (2015) Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. Journal of Applied Oral Science, 23(3): 310-314
Wutzl, A., Pohl, S., Sulzbacher, I., Seemann, R., Lauer, G., Ewers, R., i dr. (2012) Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck, 34(2): 194-200


article language: English
document type: Case Report
DOI: 10.2298/VSP151228199K
published in SCIndeks: 16/11/2017
peer review method: double-blind
Creative Commons License 4.0

Related records